QUINO-BENOXAZINE ANTIBACTERIAL COMPOUNDS

Abstract: Quino-benoxazine compounds having the formula: wherein R₂ is one or more substitutents, R₁ is a hydrogen or a carboxy-protecting group, Z is an amine group, pyridine or an aliphatic heterocyclic group and W is halogen or hyd­ rogen or, alternatively, W and Z togther form a methylene-­ dioxy bridge. The compounds have antibacterial activity.

Description: QUINO-BENZOXAZINE ANTIBACTERIAL COMPOUNDS This invention relates to new quino-benoxazine derivatives having antibacterial properties, compositions containing the new quino-benoxazine derivatives and methods of treating mammalian patients with the new quino-benoxazine derivatives. It is known that certain quinoline compounds exhibit antibacterial properties, notably certain 7-piperazinyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives which are substituted in the 1 position with an alkyl, benzyl or acetyl substituent. U.S. patent No. 4,292,317 discloses derivatives of 7piperazinyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acids wherein the 1 position is substituted by an alkyl group or a uinyl group. In U.S. Patent No. 4,284,629 there are disclosed various 4-oxo-1,4-dihydroquinoline3-carboxylic acids in which the 1 position is substituted with a cycloalkyl group. This invention relates to nouel antibacterial agents having the formula: EMI1.1 wherein R2 is one or more of hydrogen, halogen, C1 to C6 alkyl including substituted derivatives thereof, nitro, carboxyl, cyano, methylenedioxy, a group having the formula -Y-R3 wherein -Y- is -O- or -S- and R3 is hydrogen or C1 to C6 alkyl and an amine having the formula: EMI1.2 wherein R4 and R5 are each independently hydrogen or C1 to C6 alkyl. Rr ts hydrogen or a carboxy-protecting- group, - - Z is an amino group hauing the formula: EMI2.1 wherein R6 is hydrogen or C1 to C1O alkyl as well as the corresponding substituted derivatives thereof: and R7 is alkyl or substituted alkyl, as described above with reference to R6, or an amino group, a mono-(Cl to C6) alkylamino group or a di-(C1 to C6)alkylamino group. Alternatively, Z can be a pyridine ring substituted or unsubstituted, suitable substituents including C1 to C6 alkyl, halogen, a group of the formula -Y-12wherein Y is -O- or -S- and R12 is loweralkyl, hydroxy, alkanoyl containing 1 to 6 carbon atoms, alkanoylamido containing I to 6 carbon atoms and an amine of the formula: EMI2.2 wherein R13 and R14 are each independently selected from the group consisting of hydrogen, C1 to C6 alkyl and substituted derivatives thereof. Qlternatively, Z can be an aliphatic heterocyclic ring containing 4 to 7 atoms, and preferably 5 to 6 atoms as well as substituted derivatives thereof. W is halogen or hydrogen or, alternatively, W and Z together can form a methylenedioxy bridge. As used herein, the term "halogen" refers to chloro, broino, fluoro and iodo groups, while the term "C1 to c6 alkyl" refers to loweralkyl groups including methyl, ethyl, propyl, isopropyl and butyl. As used herein, the term Cl to C6 alkyl and substituted derivatives thereof refers to hydroxy and halo-substituted derivatives of C1 to C6 alkyl. Such groups include, for example, a chloromethyl group, a chloroethyl group, a chloropropyl group, a hydroxyethyl group, and a trifluoromethyl group. R2 can also be a group of the formula -Y-R3. Representative groups of this type include a hydroxy group, a mercapto group, a lower alkoxy group, such as methoxy, ethoxy, propoxy, as well as the thio analogs thereof, namely a methylmercapto group, and an ethylmercapto group. As used herein, the term "carboxy-protecting group" refers to and includes the residue of a carboxylic acid ester group. Such carboxy-protecting groups are well known to those skilled in the art, having been extensively used in the protection of carboxyl groups in the penicillin and cephalosporin fields, as described in U.S. patent Nos. 3,840,556 and 3,719,667, the disclosures of which are incorporated herein by reference. In general, such carboxyprotecting groups can be relatively easily cleaved to yield the corresponding free carboxy group. Representative protecting groups include C1-C8 alkyl (e.g., methyl, ethyl, tertiary butyl), substituted alkyl (e.g., dimethylaminoethyl), benzyl and substituted derivatives thereof such as alkoxy and nitrobenzyl groups; also suitable are acyl groups such as pivaloyloxymethyl groups. The aliphatic heterocyclic rings representing Z are, in accordance with the preferred practice of the invention, aliphatic heterocyclic rings containing 1 or 2 hetero atoms which are selected from the group consisting of S, 0 and N, with the remaining atoms in the aliphatic heterocyclic ring being carbon atoms, as well as substituted derivatives thereof. In accordance with the practice of the invention, the aliphatic - - heterocyclic ring has the formula: EMI4.1 wherein R8 is selected from the group consisting of dimethylene and a group of the formula -CH2-R-CH2 wherein R9 is selected from the group consisting of -S-, -O-, -N- and -CH2-. Rlso included are substituted derivatives of such heterocyclic rings wherein the substituent is one or more of a C1 to C6 alkyl group, an amino group having the formula: EMI4.2 wherein R10 and R11 are each independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 hydroxyalkyl, hydroxy, alkanoyl containing I to 6 carbon atoms and alkanoylamido containing 1 to 6 carbon atoms. Illustrative of such heterocyclic groups are azetidinyl groups, piperazinyl groups 4-acylpiperazinyl groups, piperidinyl groups, pyrrolidinyl groups, morpholino groups, thiomorpholino groups and homopiperazinyl groups (i.e., hexahydro-l-H-1,4-diazepinyl). Qlso included within the scope of the present invention are pharmaceutically acceptable salts of the foregoing compounds. Rs used herein, the term "pharmaceutically acceptable salts refers to nontoxic acid addition salts and alkaline earth metal salts of the compounds of Formula IQ. The salts can be prepared in situ during the final isolation and purification of the compounds of formula IQ, or separately by reacting the free base or acid functions with a suitable organic acid or base. Representative acid addition salts include the hydrochloride, hydrobromide, sulphate, bisulphate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, mesylate, citrate, maleate, fumarate, succinate, tartrate, glucoheptonate, lactobionate, lauryl sulfate salts and the like. Representative alkali or alkaline earth metal salts include the sodium, calcium, potassium and magnesium salts. It has been found that the compounds of the present invention possess antibacterial activity against a wide spectrum of gram positive and gram negative bacteria, as well as enterobacteria. The compounds of the invention are therefore useful in the antibiotic treatment of susceptible bacterial infections in both humans and animals. In addition, the compounds, by reason of their in vitro activity, may be used in scrub solutions for surface inhibition of bacterial growth. Susceptible organisms generally include those gram positive and gram negative, aerobic and anaerobic organisms whose growth can be inhibited by the compounds of the invention such as Staphylococcus; Lactobacillus. Streptococcus, Sarcina, Escherichia, Enterobacter, Klebsiella, Pseudomonas, Acinetobacter, Proteus, Citrobacter, Nisseria, Baccillus, Bacteroides, Peptococcus, Clostridium, Salmonella, Shiqella, Serratia, Haemophilus, Brucella, and other organisms. In addition to exhibiting highly effective antibacterial activity, the compounds of the invention exhibit increased and improved solubility characteristics as compared with prior quinoline-3-carboxylic acid compounds in the art. The compounds of Formula In may also be formulated into compositions together with pharmaceutically acceptable carriers for parenteral injection, for oral administration in solid or liquid form1 for rectal administration, and the like. Compositions according to the invention for parenteral injection may comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, suspensions or emulsions. Examples of suitable nonaqueous carriers, diluents, solvents or uehicles include propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable organic esters such as ethyl oleate. Such compositions may also contain adjuuants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized, for example1 by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents into the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixers containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents1 emulsifying and suspending agents a and sweetening, flavoring and perfuming agents. Compositions for rectal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax. Nctual dosage levels of active ingredient in the compositions of the invention may be varied so as to obtain an amount of active ingredient effective to achieve antibacterial activity in accordance with the desired method of administration. The selected dosage level therefore depends upon the nature of the active compound administered, the route of administration, the desired duration of treatment and other factors. Generally, daily dosage leuels of the compounds of Formula I of about 0,1 to about 750, more preferably about 0.25 to about 500 and most preferably about 0.5 to about 300 mg. of active ingredient per kg. of body weight are effective when administered orally to a mammalian patient suffering from an infection caused by a susceptible organism. If desired, the. daily dose may be divided into multiple doses for adminstration, e.g., two to four times per day. Compounds according to the invention wherein W is F can be prepared by the reaction illustrated below: EMI7.1 wherein X is a halogen and R2 and Z are the same as described above with the exclusion of pyridine. The reaction may be performed by heating a compound of the formula (II) with an amine of formula (III) at a temperature of from 200C to 2000C, and preferably from 7000 to 15000, in the presence of a suitable organic polar solvent such as dimethylsulfoxide, sulfolane, dimethylformamide, dimethylacetamide 1-methyl-2-pyrrolidinone or water. It is desirable to carry out the reaction in the presence of an acid-acceptor such as triethylamine, potassium carbonate and the like at a molar ratio of 1.0 to 1.2 mole of the acid-acceptor per mole of the compound of the formula (II). The amine (III) can also be used as acid acceptor in which 2 or more molar excess of this reagent is used. The compounds of the formula (II) may be prepared in accordance with the following reaction scheme, in which R2 is as described aboue, and X can be independently identical or nonidentical halogen: EMI8.1 EMI9.1 EMI9.2 In accordance with the foregoing reaction scheme, the 2,3,4-trihalo-5-fluorobenzoic acid (1) is treated with thionyl chloride to produce the corresponding acid chloride (2). Displacement of the acid chloride (2) with malonic acid half ester (2a) in the presence of n-butyl lithium yields the R-ketoester (3). The ss-ketoester (3) is then treated with a trialkylorthoformate (4) in the presence of an acid anhydride, preferably acetic anhydride, followed by reaction with substituted or unsubstituted 0-hydroxyaniline (5) to obtain the enaminoketoester (6). In the trialkylorthoformate (4), R1 may be an alkyl group of, for example, from 1 to 10 carbon atoms, but is preferably loweralkyl, such as ethyl. Reaction with the trialkylorthoformate is preferably conducted at elevated temperatures, such as from about 500C to about 1500C, preferably from about 100 C to about 1400C, to obtain an oily liquid, which may be isolated or unisolated, as desired (shown in brackets in the reaction scheme). Reaction of the latter with the substituted or unsubstituted 0-hydroxyaniline (5) is preferably conducted in an appropriate aprotic or nonaprotic solvent, preferably methylene chloride or tetrahydrofuran, and may be conducted at room or suitable elevated temperature, as desired. The enaminoketoester (6) is then cyclized, such as by treatment with a strong base as defined above, preferably sodium hydride, to obtain the 1-chloro-2fluoro-4-oxo-4H-quino[2,3,4-i,j][1,4]benzoxazine-5carboxylic acid ester (II) (R1=alkyl) through the intermediate (6a). Cyclization is conducted in the presence of an aprotic solvent, such as dimethoxyethane, bis(2-methoxyethyl)ether, dimethylformamide, tetrahydrofuran or chlorobenzene, and is preferably conducted at temperatures of about 2O0C to about 1450C, more preferably at the reflux temperature of the solvent employed. The ester (tri) is subjected to hydrolysis, such as by treatment with sodium hydroxide, or dilute mineral acid to form the free acid (II) (R1=H). The 4-oxo-4H-quino[2,3,4-i,j][1,4]benzoxazine5-carboxylic acid (I) (R1=H) can then be converted into the corresponding ester (I) (R1 H), if desired, by conventional esterification procedures, such as by treating the free acid (I) (R1=H) with the appropriate alcohol in the presence of an acid catalyst, by converting the free acid (I) (R1=H) into the corresponding acid chloride followed by displacement of the chloro radical with the appropriate alcohol, or by treating the sodium salt of the acid (I) (Rl=H) with a suitable reactive halide, such as chloromethylpivalate or dimethylaminoethyl chloride in dimethoxyethane to obtain, for example, the pivaloyloxymethyl ester (I) wherein R1 is -CH2OCOC(CH3)3 or dimethylaminoethyl ester (T) wherein R1 is CH2CH2N(CH3)2. The foregoing may be better understood from the following examples, which are presented for purposes of illustration and are not intended to limit the scope of the inventive concepts. Ns used in the following examples, the references to compounds, such as (1), (2), (3), etc., and to substituents, such as R, R1, R2, etc., refer to the corresponding compounds and substituents in the foregoing reaction scheme and in formulae I and II. Example 1 1-(1-piperazinyl)-2-fluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (a) To a solution of 3.9 g. of 2,3,4,5-tetrafluorobenzoic acid in 20 ml. of methylene chloride is added 4 ml. of thionyl chloride. After refluxing for 30 minutes, the reaction mixture is evaporated to dryness to give 4.95 g. of the acid chloride. This is slowly added to a dry ice-cooled solution of 3.5 g. of malonic acid monoethyl ester in 35 ml. of tetrahydrofuran, 37.9 ml. of 1.4 M. n-butyl lithium in THF, and the flask is warmed to -50C for 5 minutes and then is cooled back to -700C. To the resulting solution there is added 4.95 g, of the acid chloride in 10 ml. of THF. The cooling bath is removed, and the solution allowed to warm to room temperature after an hour. The solution is then partitioned between 1 N HC1 and ether. The ether portion is washed with NaHC03 and dried over MgS04, and then evaporated to obtain the liquid D-ketoester (3). (b) a solution of 20 g. of the above ss-ketoester (3) in 18.5 ml. of triethylorthoformate and 45 ml. of acetic anhydride is treated at 1350C for 1-1/2 hours with the remoual of the ethyl acetate formed during the reaction The solution is evaporated under reduced pressure to a mobile oil. The oil is then dissolved in 200 ml. of methylene chloride and 9.5 g. of o-hydroxyaniline is added into the solution. after 1 hour, the solution is euaporated to dryness and crystallized from 200 ml of hexane and 5 ml. of ether yielding (6), wherein R -C2H5, R2=H, X=F). (c) To a cold solution of 15 g. of the preceding product (6), R1=C2H5, X=F, R2=H in 150 ml. dimethoxyethane (DME) is slowly added 3.33 g. of a 60X sodium hydride-in-oil suspension. The mixture is refluxed for 24 hours and is cooled and diluted with water to a volume of 1.5 liters. The mixture is then filtered and the solid is washed with a 1:1 hexane/ether solution to obtain (II), (R1=C2H5, X=F, R2=H). (d) To a suspension of 7 g. of (II) (R1=C2H5, X=F, R2=H) in 30 ml. THF is added a sodium hydroxide solution (0.91 g) in 20 ml. water. The mixture is heated at 800C for 1 hour resulting in a clear solution which is evaporated under reduced pressure to dryness. The solid is dissolved in 200 ml. water and 2.5 ml. acetic acid is added. The resulting precipitate is filtered and washed with cold water, crystallized from dimethylformamide (DMF) to produce 1,2-fluoro-4-oxo-4H-quino[2,3,4-i,j][1,4]-benzoxazine5-carboxylic acid (Il) (R1-H, X=F, R2=H). (r) To a solution of 2.7 g. of 1,2-difluoro-4oxo-4H-quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (II), R1=H, X=F, R2=H) in 15 ml. of 1-methyl-2pyrrolidinone at 1150C is added 3 ml. piperazine. After stirring at 1000C for 20 hours, the solvent is removed by reduced pressure to dryness. Ethanol is added to the residue and the resulting mixture is filtered and washed with ether and then washed with very EMI12.1 ts of cold water to give (I) R=H, R2=H, The resulting dried solid (I) is suspend water and 8.5 ml. 1N HC1 is added to and warmed to dissolve. Removal of the solvent under reduced pressure gives hydrochloride salt of 1-(1-piperazinyl)-2-fluoro-4-oxo4H-quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=H, R2=H, EMI12.2 To the hydrochloride salt is added one morar equivalent of an aqueous solution of sodium hydroxide, and the resulting precipitate is filtered to obtain 1-(1-piperazinyl)-2-fluoro-4-oxo-4H-quino[2,3,4-i,j][1,4] L1,4]benoxazine-5-carboxylic acid (I). (f) Alternately, the title compound is prepared as follows: To a suspension of 5 g. of compound (II) (product of l(d) in 40 ml. 1-methyl-2pyrrolidinone at 1200C under nitrogen atmosphere is added 9.5 ml. of N-carboethoxypiperazine. Rafter 20 hours, the soluent is remoued under reduced pressure and the residue is suspended in 150 ml. ethanol and refluxed for 1/2 hour. The reaction mixture is then cooled and filtered. The resulting solid is washed with cold ethano EMI13.1 ain compound (I). (R1=H, R2=H, of 5 q. of the preceding compound (I) (R1=H, R2=H, EMI13.2 in 25 ml; of ethanol at 80 C is added 50 ml. of 10% NaOH solution. The solution is heated at 800C for 6 hours. The soluent is removed and the solid is dissolved in 100 ml water. The pH of the solution is adjusted to pH 7 by the addition of 10% acetic acid. The precipitate is filtered and washed with cold water yielding 1 piperazinyl)-2-fluoro-4-oxo-4H-quino[2,3,4-i,j][1,4] EMI13.3 carboxylic acid (I) (R1=H, R 2=H, Example 2 1-(1-(4-methyl)piperazinyl)-2-fluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid The procedure of Example 1 is repeated replacing piperazine in Example l(e) with N-methylpiperazine to obtain 1-(1-(4-methyl)piperazinyl)-2-fluoro-4-oxo4H-quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=H, R2=, EMI14.1 and its hydrochloridW salt. Example 3 1-(1-pyrrolidinyl)-2-fluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid In the described fashion as Example 1, replacing piperazine in Example l(e) with pyrrolidine, one can obtain 1-(1-pyrrolidinyl)-2-fluoro-4-oxo-4H- quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=H, R2=H, EMI14.2 Example 4 1-(1-3-hydroxypyrrolidinyl)-2-fluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid The procedure of Example 1 can be repeated replacing piperazine in Example 1(e) with 3-hydroxypyrrolidine to obtain 1-(1-3-hydroxypyrrolidinyl)-2- fluoro-4-oxo-4H-quino[2,3,4-i,j][1,4]benzoxazine-5carboxylic acid < I) (R1=R2=H, EMI14.3 Example 5 1-(1-3-aminopyrrolidinyl)-2-fluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (a) In the described fashion as Example I replacing piperazine in Example 1(e) with 3-acetamidopyrrolidine, one can obtain 1-(1-3-acetamidopyrrolidinyl)-2-fluoro-4-oxo-4H-quino[2,3,4-i,j] [1,4]benzoxazine-5carboxylic acid CI) (R1=R2=H, EMI14.4 (b) The product of the above reaction can be hydrolyzed with hydrochloric acid at 80 C to give 1-(1-3-aminopyrrolidinyl)-2-fluoro-4-oxo-4H-quino [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=R2=H, EMI14.5 and its hydrochloride salt. Example 6 1-(1-3-methylaminopyrrolidinyl)-2-fluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (a) In the described fashion as Example 1 replacing piperazine in Example 1(e) with 3-N-formyl-Nmethylpyrrolidinyl, one can obtain 1(1-3-N-formyl-N- methylaminopyrrolidinyl)-2-fluoro-4-oxo-4H-quino 2,3,4-i,jJC1,41benoxazine-5-carboxylic acid (I) (R1=R2=H. EMI15.1 N(CH3)CHO). (b) The product of the above reaction can then be hydrolyzed with hydrochloric acid at 800C to give 1-C 1-3-methylaminopyrrolidinyl)-2-fluoro-4-oxo-quino- [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I), (RloR2=H, EMI15.2 and its hydrochloride salt. Example 7 1-(1-3-dimethylaminopyrrolidinyl)-2-fluoro-4-oxo 4H-quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid The procedure of Example 1 is repeated replacing piperazine in Example l(e) with 3-dimethyl aminopyrrolidine to obtain 1-(1-3-dimethylaminopyrrolidinyl)-2-fluoro-4-oxo-4H-quino[2,3,4-i,j][1,4]benoxazine-5-carboxylic acid (I) and its hydrochloride salt (R1=R2=H' EMI15.3 Example 8 1-(1-pyperidinyl)-2-fluoro-4-oxo-4H-quino [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid The procedure of Example 1 can be repeated replacing piperazine in Example l(e) with piperidine to obtain 1-(1-pyperidinyl)-2-fluoro-4-oxo-4H-quino [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=R2=H, EMI15.4 Example 9 1-(4-morpholinyl)-2-fluoro-4-oxo-4H-quino [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid In the described fashion as Example 1, replacing piperazine in Example lte) with morpholine, one can obtain 1-(4-morpholinyl)-2-fluoro-4-oxo-4H- quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=R2=H, EMI16.1 Example 10 1-(4-thiomorpholinyl)-2-fluoro-4-oxo-4H-quino [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid The procedure of Example I can be repeated replacing piperazine in Example iCe) with thiomorpholine to obtain 1-(4-thiomorpholinyl)-2-fluoro-4-oxo-4H-quino [2,3,4-i,j EMI16.2 -5-carboxylic acid (I) (R1=R2=H, Example 11 1-(1-3-dimethylpiperazinyl)-2-fluoro-4-oxo 4H-quino-[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid In the described fashion as Example 1, replacing piperazine in Examle lle) with 2,6-dimethylpiperazine, one obtains 1-(1-3,5-dimeethylpiperazinyl)2-fluoro-4-oxo-4H-quino-[2,3,4-i,j][1,4]benzoxazine-5carboxylic EMI16.3 its hydrochloride salt. (R 1=R2=H, Example 12 1-(1-homopiperazinyl)-2-fluoro-4-oxo-4H-quino- [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid The procedure of Example 1 is repeated replacing piperazine in Example 1(e) with homopiperazine to obtain 1-(1-homopiperazinyl)-2-fluoro-4-oxo-4H-quino [2,3 ,4-i.j] El ,4]benoxazine-5 -carboxylic acid (I) and 1cs hydrochloride salt (R1=R2=H, EMI17.1 Example 13 1-dimethylamino-2-fluoro-4-oxo-4H-quino [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid In the described fashion as Example 1, replacing piperazine in Example l(e) with dimethylamine, one can obtain 1-dimethylamino-2-fluoro-4-oxo-4H-quino [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) CR1=R2=H, Z=N(CH3)2). Example 14 1-(N-2-hydroxyethylamino)-2-fluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid The procedure of Example 1 can be repeated replacing piperazine in Example l(e) with N-2-hydroxyethylamine to obtain 1-(N-2-hydroxyethylamino)-2-fluoro- 4-oxo-4H-quino-[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=R2=H, Z=NHC2H4-OH). Example 15 1-hydrazyl-2-fluoro-4-oxo-4H-quino [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid In the described fashion as Example 1, replacing piperazine in Example l(e) with hydrazine, one can obtain 1hydrazyl-2-fluoro-4-oxo-4H-quino[2,3,4-i,j] [1,4]benzoxazine-5-carboxylic acid (R1=R2=H, Z=NHNH2). Example 16 1-(1-piperazinyl)-2,10-difluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (a) In the described fashion as Example l(b), replacing 2-hydroxyaniline with 2-hydroxy-4-fluoro aniline, one can obtain the enaminoketoester (6) =C2H5, R=10-fluoro, X=F). (b) By following the Eample 1(c) and l(d). the preceding compound (6) can yield 1,2,10-trifluoro-4-oxo- 4H-quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (II), (R1=H, X=F, R2=10-fluoro. (c) In the described fashion as Example l(e), the aboue acid for can give the desired 1-(1-pipera- zinyl)-2,10-difluoro-4-oxo-4H-quino[2,3,4-i,j][1,4]benoxazine-5-carboxylic acid (I) and its hydrochloride salt (R1=H, R2=10-fluoro, EMI18.1 Example 17 In the described fashion as Example 1(e), replacing the acid (II) (R1=R2=H, X=F) with the acid (II) of the product of Example 16(b) (R1=H, R 2=1O-fluoro, X=F) and also replacing piperazine with an appropriate amine such as N-methylpiperazine, pyrrolibine, 3-hydroxypyrrolidine, 3-acetaminopyrrolidine, 3-N-formyl-N-methylaminopyrrolidine, 3-dimethylaminopyrrolidine, piperidine, morpholine, thiomorpholine, 2,6-dimethylpiperazine, homopiperazine, diethylamine and 2,2-dimethylhydrazine, one can obtain the following compounds: (a) 1-(1-4-methylpiperazinyl)-2,10-difluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) and its hvdrochloride salt (R1=H, R2=10-fluoro, EMI18.2 (b) 1-Cl- pyrrolidinyl)-2,10-difluoro -4-oxo-4H-quino [2,3,4-i,j][1,4] benoxazine-5-carboxylic acid (I) (R1=H, R2=1O-fluoro, EMI18.3 (c) 1-(1-3-hydroxypyrrolidinyl)-2,10-difluoro-4-oXo-4H¯ quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1H, R2=10-fluoro, EMI18.4 d) 1-(1-3-acetamidopyrrolidinyl)-2,10-difluoro-4-oxo 4H-quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=H, R2=10-fluoro, EMI19.1 (e) 1-(1-3-N-formyl-N-methylaminipyrrolidinyl)-2,10 difluoro-4-oxo-4H-quino[2,3,4-i,j][1,4]benzoxazine5-carboxylic acid (I) (R1=H, R2=10-fluoro, EMI19.2 (f) 1-(1-3-dimethylaminopyrrolidinyl)-2,10-difluoro-4-oXo -4H-quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=H, R2=10-fluoro, EMI19.3 and its hydrochloride salt. (g) 1-(1-piperidinyl)-2,10-difluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1H, R2=10-fluoro EMI19.4 (h) 1-(4-morpholinyl)-2,10-difluoro-4-oxo-4H-quino- [2,3,4-i,j][1,4]beno xazine-5-car boxylic acid (I) (R1=H, R2=10-fluoro, EMI19.5 (i) 1-(4-thiomorpholinyl )-2, lO-difi uoro-4-oxo-4Hquino[2,3,4-i,j][1,4]ben oxazine-5-ca rboxylic - acid (I) (R1=H, R2=10-fluoro, EMI19.6 (j) 1-(1-3,5-dimethylpiperaz inyl)-2 difluoro-4-oxo-4Hquino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=H, R2=10-fluoro, EMI19.7 ) and its hydrochloride salt. (k) 1-(1-homopiperazinyl)-2,10-difluoro-4-oxo-4Hquino[2,3,4-i,j][1,4]be EMI19.8 carboxylic acid (I) (R1H, R2=10-fluoro, and its hydrochloride salt. (1) 1-diethylamino-2,10-difluoro-4-oxo-4H-quino [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=H, R2=10-fluoro, Z=N(CH3)2). (m) 1-N,N-dimethylhydrazyl-2,10-difluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) (R1=H, R2=1O-fluoro, Z=NHN(CH3)2). Example 18 In the described fashion of Example 5(b), the compounds of Examples 17(d) and 17(e) can give the followng 2 compounds. (a) 1-(1-3-aminopyrrolidinyl)-2,10-difluoro-4-oxo quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) and its hydrochloride salt (R1=H, R2=1-fluoro, EMI20.1 (b) 1-(1-3-methylaminopyrrolidinyl)-2,10-difluoro-4 oxo-4H-quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (I) and its hydrochloride salt (R R2=10-fluoro, EMI20.2 Example 19 In the described fashion as Example 1(a-d), replacing o-hydroxyaniline wit EMI20.3 opriate substituted 2-hydroxyaniline one can obtain the additional substitu ifluoro-4oxo-4H-quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (II) as listed in Table I. Table I EMI20.4 <tb> Substituted <SEP> 2- <SEP> Compound <SEP> II) <tb> hydroxyanilin <SEP> NH <SEP> (R1=H,^X=F) <SEP> obtained <tb> <SEP> OHX <SEP> 1 <tb> <SEP> R2 <SEP> e <SEP> R2 <SEP> R2 <tb> (a) <SEP> 4-methoxy <SEP> 10-methoxy <tb> (b) <SEP> 4-methyl <SEP> 10-methyl <tb> (c) <SEP> 4-chloro <SEP> 10chloro <tb> (d) <SEP> 4,6-difluoro <SEP> 8,10-difluoro <tb> (e) <SEP> 4,5-methylenedioxy <SEP> 9,10-methylenedioxy <tb> (f) <SEP> 4-hydroxy <SEP> lQ-hydroxy <tb> (g) <SEP> 4-dimethylamino <SEP> 10-dimethylamino <tb> (h) <SEP> 5-fluoro <SEP> 9-fluoro <tb> Example 20 In the described fashion of Example l(e), replacing the acid (II) (R1=H, R2=H, X=F) with the acid (II) of the compounds listed in Table I of Example 19 and also replacing piperazine with an appropriate amine such as N-methylpiperazine, pyrrolidine, 3-hydroxypyrrolidine, 3-acetamidopyrrolidine, 3-N-formyl-N-methylaminopyrrolidine, 3-dimethylaminopyrrolidine, piperidine morpholine, thiomorpholine, 2,6-dimethylpiperazine, homopiperazine, dimethylamine and 2,2-dimethylhydrarine, and extra hydrolysis step if required as in Example 5(b), one can obtain the following additional compounds (I) as summarized in Table II. Table II Piperazine replacement Compound IKI used Compound I obtained (R1=H, X=F) (R1=H) ZH R2 R2 Z 1. piperazine 8,10-difluoro 8,10-difluoro piperazinyl 2. piperazine 9,10-methylenedioxy 9,10-methylenedioxy piperazinyl 3. piperazine 10-hydroxy 10-hydroxy piperazinyl 4. piperazine 10-methyl 10-methyl piperazinyl 5. 4-methylpiperazine 8,10-difluoro 8,10-difluoro 4-methylpiperazinyl 6. 4-methylpiperazine 9,10-methylenedioxy 9,10-methylenedioxy 4-methylpiperazinyl 7. 4-methylpiperazine 10-hydroxy 10-hydroxy 4-methylpiperazinyl 8. 4-methylpiperazine 10-chloro 10-chloro 4-methylpiperazinyl 9. 3-acetamidopyrrolidine 8,10-difluoro 8,10-difluoro 3-aminopyrrolidinyl 10. 3-acetamidopyrrolidine 9,10-methylenedioxy 9,10-methylenedioxy 3-aminopyrrolidinyl 11. 3-acetamidopyrrolidine 10-hydroxy 10-hydroxy 3-aminopyrrolidinyl Table II (continued) Piperazine replacement Compound II used Compound I obtained (R1=H, X=F) (R1=H) ZH R2 R2 Z 12. 3-acetamidopyrrolidine 9-fluoro 9-fluoro 3-aminopyrrolidinyl 13. 3-methylacetamido pyrrolidine 8,10-difluoro 8,10-difluoro 3-methylaminopyrrolidinyl 14. 3-methylacetamido pyrrolidine 9,10-methylenedioxy 9,10-methylenedioxy 3-methylaminopyrrolidinyl 15. 3-methylacetamido pyrrolidine 10-hydroxy 10-hydroxy 3-methylaminopyrrolidinyl 16. 3-methylacetamido pyrrolidine 10-dimethylamino 10-dimethylamino 3-methylaminopyrrolidinyl 17. pyrrolidine 10-methoxy 10-methoxy pyrrolidinyl 18. 3-dimethylamino pyrrolidine 9,10-methylenedioxy 9,10-methylenedioxy 3-dimethylaminopyrrolidinyl 19. 3-dimethylamino pyrrolidine 8,10-difluoro 8,10-difluoro 3-dimethylaminopyrrolidinyl 20. 3-hydroxypyrroldine 9-fluoro 9-fluoro 3-hydroxypyrrolidinyl Table II (continued) Piperazine replacement Compound II used Compound I obtained (R1=H, X=F) (R1=H) ZH R2 R2 Z 21. piperidine 10-hydroxy 10-hydroxy piperidinyl 22. morpholine 10-chloro 10-chloro morpholinyl 23. thiomorpholine 10-methyl 10-methyl thiomorpholinyl 24. N,N-dimethylhydrazine 10-methoxy 10-methoxy N,N-dimethylhydrazyl 25. dimethylamine 10-chloro 10-chloro dimethylamino 26. homopiperazine 8,10-difluoro 8,10-difluoro homopiperazinyl 27. 2,6-dimethylpiperazine 9,10-methylenedioxy 9,10-methylenedioxy 3,5-dimethylpiperazinyl The compound wherein W and Z form a methylenedioxy bridge may be prepared in accordance with the following reaction scheme a in which R2 is as described above and X can be independently identical or non-identical halogen. EMI25.1 In accordance with the foregoing reaction scheme, 2,3-dibromo-4,5-methylenedioxybenzoyl chloride is reacted with malonic acid halfester (8) in the presence of n-butyllithium to give the ss-ketoester (9). The ss-ketoester (9) is then treated with a trialkylorthoformate (10) in the presence of an acid anhydride, followed by reaction with substituted or unsubstituted 2-hydroxyaniline ±11) to obtain the enaminoketoester (12). This enaminoketoester (12) is then cyclized by treatment with a strong base such as sodium hydride to obtain the 1,2-methylenedioxy-4-oxo-4H-quino [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid ester (IV) CR 1=alkyl). The ester (IV) is subjected to hydrolysis either with hydrochloric acid or sodium hydroxide to form the free acid (IU) CR1=H). As used in the following examples a the references to compounds such as (7), (8), (9), etc. and to the substituents, such as R, R1, R2 etc. refer to the corresponding compounds and substituents in the foregoing reaction scheme and informula IU. Example 21 1, 2-methylenedioxy-4-oxo-4H-quino- [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (a) To a dry ice cooled solution of 0.85 g. malonic acid monoethyl ester in 25 ml. of tetrahydrofuran (THF) is slowly added 9.2 ml. of 1.4 M n-butyl lithium in THF and the flask is warmed to -5 C. rafter 5 minutes, the solution is cooled back to -70 C. After 1.3 g. of the acid chloride (7) (X=Br) is added, the cooling bath is removed and warmed up to room temperature over an hour, The solution is then partitioned between 1 N HCl and ether. The ether portion is washed with NaHC03 and is dried over MgS04, then euaporated to obtain a pale yellow oil which is then purified over a silica gel column to yield ss-ketoester (9) (R1=C2H5 X=Br). (b) To a solution of 1.25 g. of ss-ketoester (9) (R1=CH5, X=Br) in 0.8 ml. of triethylorthoformate and 5 ml. of acetic anhydride is heated at 135 C for 1-1/2 hours with the removal of the ethyl acetate formed during the reaction. The solution is evaporated under reduced pressure to a mobile oil. The oil is then dissolved in 5 ml. of methylene chloride and 0.41 g. of 2-hydroxy-aniline is added into the solution. After I hour, the solution is euaporated to dryness and crystallized from ethylacetate yielding (12), wherein R1=C2H5, X=Br and R2=H. (c) To a solution of 3.6 g. of the preceding product (12), (Rl=C2H5, R2=H, X-Br) in 30 ml. dimethoxyethane is slowly added 0.56 g. of a 60% sodium hydride-in-oil suspension. The mixture is refluxed for 20 hours and is cooled and diluted with water to a volume of 100 ml. The mixture is then filtered and the solid is washed with a 1:1 hexane/ether solution to obtain (IV) CR1=C2H5a R2=H). (d) To a suspension of 1.6 g. of (14) (R1=C2H5, R2=H) in 20 ml. THF is added a sodium hydroxide solution (0.2 g. in 20 ml. water). The mixture is heated at 80OC for 2 hours resulting in a clear solution which is evaporated under reduced pressure to dryness. The solid is dissolved in 200 ml. water and 1 ml. acetic acid is added. The resulting precipitate is filtered and washed with cold water to produce 1,2-methylendioxy-4-oxo-4H-quino[2,3,4-i,j] [1,4]benoxazine-5-carboxylic acid (IV) (R1=H, R2=H). Example 22 1,2-methylendioxy-10-fluoro-4-oxo-4H quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid The procedure of Example 21 can be repeated replacing 2-hydroxyaniline in 21(b) with 2-hydroxy4-fluoroaniline to obtain 1,2-methylenedioxy-10-fluoro4-oxo-4H-quino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (IV), R1=H R R2=10-fluoro. Example 23 In the described fashion as Example 21, replacing 2-hydroxyaniline in Example 21(b) with appropriate substituted 2-hydroxyaniline, one can obtain the additional substituted 1,2-methylenedioxy-4-oxo-4Hquino[2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid (IV), (R1=H) as listed in Table III. Table III EMI28.1 <tb> Substituted <SEP> 2- <SEP> Compound <SEP> IV <SEP> obtained <tb> hydroxyaniline <SEP> NH2 <SEP> (R1=2 <tb> <SEP> R= <SEP> < <SEP> 2 <SEP> R2= <tb> (a) <SEP> 6-fluoro <SEP> 8-fluoro <tb> (b) <SEP> 5-fluoro <SEP> 9 <SEP> 9-fluoro <tb> (c) <SEP> 3-fluoro <SEP> ll-fluoro <tb> (d) <SEP> 4,6 <SEP> difluoro <SEP> 8,10--difluoro <tb> (c) <SEP> 4-chioro <SEP> 10 <SEP> -chloro <tb> ( <SEP> 4 <SEP> methyl <SEP> 10 <SEP> methyl <tb> (g) <SEP> 4.5-methylcncdioxy <SEP> 4,5 <SEP> methylonedioxy <SEP> 9,10-methylenedioxy <tb> (h) <SEP> 4 <SEP> hydroxy <SEP> 10- <SEP> hydroxy <tb> (i) <SEP> 4-methoxy <SEP> 10 <SEP> -methoxy <tb> The compounds wherein X is a pyridine ring may be prepared in accordance with the following reaction scheme: : EMI28.2 In accordance with the foregoing reaction scheme wherein X is a halogen or a leaving group a the acetophenone (13) is reacted with a dialkoxycarbonate (14) in the presence of a strong base to obtain the corresponding ss-ketoester (15). In the dialkoxycarbonate (14), R1 may be an alkyl group of, for example, 1 to 10 carbon atoms, but is preferably loweralkyl, such as ethyl. Suitable bases include metal hydrides, such as sodium hydroxide, potassium hydride and the like, as well as metal alkoxides in alcohol, such as sodium ethoxide in ethanol. The preferred base is sodium hydride. Formation of the B-ketoester (15) is facilitated by reacting the acetophenone (13) with the dialkoxycarbonate (14) at elevated temperatures, such as from about 200C to about 120 C, and preferably from about 30 C to about 900C until completion of the reaction. The ss ketoester may then be separated from the reaction mixture in a conventional manner. The (3-ketoester (15) is then treattd with a trialkylorthoformate (16) in the presence of an acid anhydride. preferably acetic anhydridea followed by reaction with substituted or unsubstituted 2 hydroxyaniline (17) to obtain the enamino-ketoester (18). In the trialkylorthoformate (16 R12 may be an alkyl group of, for example, from 1 to 10 carbon atoms, but is preferably loweralkyl, such as ethyl. Reaction with the trialkylorthoformate is preferably conducted at elevated temperatures, such as from about 50 C to abut 150 C, and preferably from about 100 C to about 140 C, to obtain an oily liquid, which may be isolated or unisolated, as desired (shown in brackets in the reaction scheme). Reaction of the latter with the substituted or unsubstituted 2-hydroxyaniline (17) is preferably conducted in an appropriate aprotic or non-aprotic solvent, preferably methylene chloride or tetrahydrofuran, and may be conducted at room or suitable elevated temperatures, as desired. The enamino-ketoester (18) is then cyclized, such as by treatment with a strong base as defined above, preferably sodium hydride, to obtain the 1-(4-pyridyl)-4-oxo-4H-quino[2,3,4-i,j][1,4]benzoxazine 5-carboxylic acid ester {U) R1=alkyl) Oxo is conducted in the presence of an aprotic soluent, such as dimethoxyethane, dimethylformamide, tetrahydrofuran or chlorobenzene, and is preferably conducted at temperatures of about 200C, to about 140C, and more preferably at the reflux temperature of the solvent employed. The ester (V) (R1=alkyl) is subjected to hydrolysis such as by treatment with sodium hydroxide, or mineral acid, to form the free acid (V). The 1-(4-pyridyl)-4-oxo-4H-quino[2,3,4-i,j] [1,4]benzoxazine-5-carboxylic acid (V) (R1=H) can be converted into the corresponding ester, if desired, b conventional esterification procedures, such as by treating the free acid (V) with the appropriate alcohol in the presence of an acid catalyst, by converting the free acid (V) into the corresponding acid chloride followed by displacement of the chloro radical with the appropriate alcohol, or by treating the sodium salt of the acid (U) with a suitable reactive halide, such as chloromethylpiualate in dimethoxyethane to obtain, for example, the pivaloyloxymethyl ester. The foregoing may be better understood from the following examples, which are presented for purposes of illustration and are not intended to limit the scope of the inventive concepts. fls used in the following examples, the references to compounds, such as (13), (14), (15), etc., and to substituents, such as R1, R2, etc., refer to the corresponding compounds and substituents in the foregoing reaction scheme and in formula V. Example 24 1-(4-pyridyl)-2-fluoro-4-oxo-4H quinof2,3,4-i,it1,436enoxazine-S-carbox acid (a) R cold solution of 28.4 g. 2,3-dichloro4-(4-pyridyl)-5-fluoroacetophenone in 350 ml. diethylcarbonate is slowly added to 8.0 g. 60% sodium hydridein-oil suspension. The mixture is heated at 80 C for 3 hours, then poured into 700 ml. ice cold water solution containing 25 ml. acetic acid. The mixture is extracted with three 400 ml. portions of ether. The organic phase is dried over MgS04. euaporated and the obtained oil is purified through silica gel column to give pure (15). (X5C1, R1=C2H5, W=F). (b) R solution of 16.6 g. of ss-ketoester (15) (R1=C2H5, X=Cl, W=F) in 14 ml. of triethylorthoformate and 35 ml. of acetic anhydride is heated at 135 C for 1-1/2 hours with the removal of the ethyl acetate formed during the reaction. The solution is evaporated under reduced pressure to a mobile oil. The oil is then dissolved in 150 ml. of methylene chloride and 7.5 g. of 2-hydroxyaniline is added into the solution. Rfter 1 hour, the solution is evaporated to dryness yielding (18), wherein R1=C2H5, X=Cl, R2=H. W=F. (c) To a cold solution of 14 9. of the preceding product (18) (R1=C2H5, R2=H. X=Cl, W=F), in 140 ml tetrahydrofuran (THF) is slowly added 2.5 g. of a 60% sodium hydride-in-oil suspension. The mixture is refluxed for 6 hours and is cooled and diluted with water to a volume of 1.5 liters. The mixture is then filtered and the solid is washed with 1:1 hexane/ether solution to obtain (V) wherein R1=C2H5 W=F. R2=H). (d) To a suspension of 5 g. of (V) (R1=C2H5, W=F, R2=H) in 30 ml. of THF is added a sodium hydroxide solution (0.63 g. in 10 ml. water). The mixture is heated at 800C for 2 hours resulting in a clear solution which is euaporated under reduced pressure to dryness. The solid is dissolved in 200 ml. water, and 2 ml. acetic acid is added. The resulting precipitate is filtered and washed with cold water, to produce 1-(4-pyridyl)-2-fluoro-4-oxo-4H-quino C2,3,4-i,jIC1,41benoxazine-5-carboxylic acid (V) (R1=H, R2=H, W=F). Example 25 1-(4-pyridyl)-2,10-difluoro-4-oxo-4H-quino [2,3,4-i,j][1,4]benzoxazine-5-carboxylic acid The procedure of Example 24 can be repeated replacing 2-hydroxyaniline with 2-hydroxy-4-fluoroaniline in Example 24(b) to obtain 1-(4-pyridyl)-2,10- difluoro-4-oxo-4H-quino[2,3,4-i,j][1,4]benzoxazine5-carboxylic acid (I), (R1=H, R2=10-fluoro, W=F). Example 26 In the described fashion as Example 24 replacing 2-hydroxyaniline in Example 24(b) with 2,4-dihydroxy- aniline, one can obtain 1-(4-pyridyl)-2-fluoro-10hydroxy-4-oxo-4H-quino[2,3,4-i,j][1,4]benzoxazine-5carboxylic acid (V) (R1=H, R2=10-hydroxy, W=F). Example 27 The procedure of Example 24 can be repeated replacing 2-hydroxyaniline in Example 24(b) with 2hydroxy-4-methoxyaniline to obtain 1-(4-pyridyl)-2fluoro-10-methoxy-4-oxo-4H-quino[2,3,4-i,j][1,4]benoxazine-5-carboxylic acid (V), (R1=H, R 2=1O-methoxy, W=F). Example 28 In the described fashion as Example 24 replacing 2-hydroxyaniline in Example 24(b) with various substituted 2-hydroxyaniline, one can obtain additional substituted 1-(4-pyridyl)-2-fluoro-4-oxo-4H-quino C2,3,4-i,3t1,4fbenoxazine-5-carboxylic acid CV) as summarized in Table IV. Table IV EMI32.1 <tb> 2-Hydroxyaniline <SEP> Compound <SEP> V <SEP> obtained <tb> Replacement <SEP> EH <SEP> (W=F, <SEP> R1=H) <tb> <SEP> HO <tb> <SEP> HoW <SEP> R2= <tb> (a) <SEP> 6-fluoro <SEP> 2 <SEP> 8-fluoro <tb> (b) <SEP> 5-fluoro <SEP> 9-fluoro <tb> (c) <SEP> 3-fluoro <SEP> I <SEP> 1-fluoro <tb> (d) 4,6-difluoro 8,10-difluoF; (e) 4-chloro 10-fluoro (f) 4-methyl 10-methyl C) 4,5-methylenedioxy 9,10-methylenedioxy Example 29 In the described fashion as Example 24 replacing 2,3-dichloro-4-(4-pyridyl)5-fluoroacetophenone in Example 24(a) with 2,3-dichloro-4-(4-pyridyl)aceto- phenone and optionally, 2-hydroxyaniline in Example 24(b) with 2-hydroxy-4-fluoroaniline or 2-hydroxy-4,5methylenedioxyaniline, one can obtain the following three compounds: : (a) 1-(4-pyridyl)-4-oxo-4H-quino[2,3,4-i.j] 1,43benoxazine-5-carboxylic acid (V) (R1=H, W=H, R (b) 1-(4-pyridyl)-10-fluoro-4-oxo-4H- quino[2,3,4-i.j][1,4]benoxazine-5-carboxylic acid (V) (R1=H, W=H, R2=10-fluoro). (c) 1-(4-pyridyl)-9,10-methylenedioxy- 4-oxo-4H-quino[2,3,4-i.j][1,4]benoxazine-5-carboxylic acid (V) (R1=H, W=H, R2=9,10-methylenedioxy). It will be understood that uarious changes and modifications can be made in the details of formulation, procedure and use without departing from the spirit of the invention, especially as defined in the following claims.

Claims: CLAIMS 1. A compound having the formula EMI34.1 wherein R1 is hydrogen or a carboxy protecting group; R2 is one or more groups selected from the group consisting of hydrogen, halogen, nitro, carboxyl, methylenedioxy, cyano, C1 to C6 alkyl and substituted derivatives thereof, a group having the formula: -Y-R3 wherein -Y- is -O- or -S- and R3 is hydrogen or C1 to C6 alkyl, and an amine group having the formula: EMI34.2 wherein R4 and R5 are independently hydrogen or C1 to C alkyl; W is halogen or hydrogen; and Z is selected from the group consisting of an aliphatic heterocyclic ring having the formula EMI34.3 wherein R8 is methylene, dimethylene or a group of the formula -CH2-CH2-R9-CH2- or -CH2-R9-CH2 - wherein Rg is selected from the group consisting of -S-, -0- and -N-; substituted derivatives thereof wherein one or more substituents are selected from the group consisting of C1 to C6 alkyl, C1 to C6 hydroxyalkyl, hydroxy, alkanoyl containing 1 to 6 carbon atoms, alkanoylamido containing 1 to 6 carbon atoms and an amine of the formula EMI34.4 wherein R10 and R are each independently selected 11 from the group consisting of hydrogen, C1 to C6 alkyl and substituted derivatives thereof; an amino group of the formula EMI35.1 wherein R6 is hydrogen or C1 to C1O alkyl and substituted derivatives thereof; and R7 is selected from the group consisting of C1 to C10 alkyl and substituted derivatives thereof. an amine group. a mono-(C1 to C6) alkylamino group and a di-(C1 to C6) alkylamino group; a pyridine ring of the formula EMI35.2 or substituted derivatives of the pyridine ring wherein the pyridine ring is substituted with one or more substituents selected from the group consisting of C1 to C6 alkyl, halogen, a group of the formula -Y-R12 wherein Y is -O- or -S- and R12 is loweralkyl, hydroxy, alkanoyl containing 1 to 6 carbon atoms. alkanoylamido containing 1 to 6 carbon atoms and an amine of the formula: EMI35.3 wherein R13 and R14 are each independently selected from the group consisting of hydrogen, C1 to C6 alkyl and substituted derivatives thereof; or, alternatively, W and Z together may form a methylenedioxy bridge. and pharmaceutically acceptable salts thereof. 2. n compound as defined in Claim 1 wherein W is F; Z is piperazinyl, substituted piperazinyl, 4acylpiperazinyl, or 3-amino or substituted aminopyrrolidinyl and R2 is one or more of an alkyl group, a hydrogen group, a halogen group, a hydroxy group and a methylenedioxy group. and pharmaceutically acceptable salts thereof. 3. compound as defined in Claim 2 wherein R2 is hydrogen; Z is piperazinyl or 4-methylpiperazinyl; and R1 is hydrogen. 4. R compound as defined in Claim 2 wherein R2 is lO-fluoro or 8,10 difluoro; Z is piperazinyl, 4-methylpiperazlnyl, 3-aminopyrrolidinyl, 3-methylaminopyrrolidinyl or dimethylaminopyrrolidinyl; and R1 is hydrogen. 5. d compound as defined in Claim 1 wherein W and Z together form a methylenedioxy bridge; R1 is hydrogen or a carboxy protecting group; R2 is one or more groups selected from the group consisting of hydrogen, halogen, nitro methylenedioxy. carboxyl. cyano, C1 to C6 alkyl and substituted derivatives thereof. a group having the formula: -Y-R3 wherein -V- is -O- or. -S- and R3 is hydrogen or C1 to C6 alkyl1 and an amine group having the formula: EMI36.1 wherein R4 and R5 are independently hydrogen or C1 to C6 alkyl; and, pharmaceutically acceptable salts thereof. 6. compound as defined in Claim 5 wherein R2 is hydrogen, loweralkyl, 10-fluoro, methylenedioxy, or 8,10-difluoro group; and R1 is hydrogen. 7. n compound as defined in Claim 1 wherein R1 is hydrogen or a carboxy protecting group; W is halogen or hydrogen; R2 is one or more groups selected from the group consisting of hydrogen, halogen, nitro, carboxyl. methylenedioxy, cyano, C1 to C6 - - -alkyl and substituted derivatives thereof. a group having the formula: -V-R3 wherein -V- is -0- or -S- and R3 is hydrogen or C1 to C6 alkyl, and an amine group having the formula: EMI37.1 wherein R4 and R5 are independently hydrogen or C1 to C6 alkyl; and Z is a pyridine ring and pharmaceutically acceptable salts thereof. 8. a compound as defined in Claim 7 wherein R2 is hydrogen, fluoro, difluoro or methylenedioxy; R1 is hydrogen, and W is flucro or hydrogen.

Inventors: CHU, DANIEL TIM-WO
Applicants: ABBOTT LABORATORIES
Application year: 1985
Main classification: C07D498
IPC codes: A61K31, A61P31, C07D498